Exploring surrounding epigenetic influences in Ewing sarcoma
Dr Sara Sánchez Molina is investigating how a certain gene drives Ewing sarcoma in order to find a better way to treat it.
Exploring potential indicators of the likely course of disease: analysing blood samples from patients recruited to the rEECur clinical trial
Professor Martin McCabe aims to understand whether blood-based biomarkers could help predict Ewing sarcoma survival.
Investigating the shape of fusion genes in rhabdomyosarcoma
How the 3D shape of fusion gene genetic code affects cancer cell behaviour and whether shape-modifying medicines could mitigate these effects.
Predicting high-risk rhabdomyosarcoma at diagnosis to improve outcomes
Assessing rhabdomyosarcoma risk prediction markers based on the biological conditions in the tumour, like low oxygen levels, few blood vessels, and genetics.
Determining the best approach to treat children with relapsed anaplastic large cell lymphoma
Looking at why ALCL sometimes relapses with a new targeted treatment, and understanding how to optimise this treatment approach.
What are the effects of radiation and chemotherapy on children’s developing brains?
Looking at the differences between healthy brain cells before and after treatment to uncover the mechanisms behind brain-related late effects.
Why do some leukaemia patients have long-term problems with learning and memory
Finding a way to identify patients at risk of brain related side effects from leukaemia treatment, and gathering data to inform future treatment options.
Studying the origins of childhood acute myeloid leukaemia to identify targets for kinder and more effective treatments
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
Detecting lingering brain cancer cells before a tumour grows back
Ependymoma comes back after treatment around half of the time, because some cancer cells are still alive. If doctors could identify these cells and diagnose relapsed ependymoma sooner, children could start treatment earlier.